✦ LIBER ✦

INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE

✍ Scribed by WAGNER, JOSEPH R.; WALTHER, McCLELLAN M.; LINEHAN, W. MARSTON; WHITE, DONALD E.; ROSENBERG, STEVEN A.; YANG, JAMES C.

Book ID: 121771688
Publisher: Lippincott Williams and Wilkins
Year: 1999
Tongue: English
Weight: 331 KB
Volume: 162
Category: Article
ISSN: 0022-5347
DOI: 10.1097/00005392-199907000-00011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose interleukin-2 immunotherapy is

High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis

✍ JOHN P. BRUSKY; FAWEZ GAILANI; APURBA PATHAK; HATEL PATEL; SHERIF ABOSEIF 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Leukocyte orchestration in blood and tum

Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma

✍ Frede Donskov; Karen Marie Bennedsgaard; Marianne Hokland; Niels Marcussen; Rune 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 382 KB

Surgical resection of metastatic renal c

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy

✍ Dr. Richard M. Shery; Harvey I. Pass; Steven A. Rosenberg; James C. Yang 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB 👁 2 views

Thirty-one patients with disseminated melanoma or renal cell cancer (RCC) who had a limited relapse or persistent disease after a partial or complete response to interleukin-2 (IL-z)-based immunotherapy underwent resection of progressing tumors or residual sites of disease. There were no surgery-rel

Carbon anhydrase IX specific immune resp

Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy

✍ Rasmussen, Susanne; Donskov, Frede; Pedersen, Johannes W.; Wandall, Hans H.; Buu 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 521 KB

C-REACTIVE PROTEIN: A BIOMARKER OF SURVI

C-REACTIVE PROTEIN: A BIOMARKER OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH SUBCUTANEOUS INTERLEUKIN-2 BASED IMMUNOTHERAPY

✍ CASAMASSIMA, ADDOLORATA; PICCIARIELLO, MARGHERITA; QUARANTA, MICHELE; BERARDINO, 📂 Article 📅 2005 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 75 KB

The effect of low-dose interleukin-2-bas

The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma

✍ Rafael M. Nagler; Eliyahu Gez; Rafael Rubinov; Dov Laufer; Hanna Ben-Aryeh; Dian 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 73 KB